Development of resistance to tyrosine kinase inhibitors (TKIs) targeting the BCR/ABL fusion protein represents a major challenge in the treatment of chronic myeloid leukemia (CML). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.